• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
ACADIA Pharmaceuticals Inc. (ACAD) - Financial and Strategic SWOT Analysis Review - Product Image

ACADIA Pharmaceuticals Inc. (ACAD) - Financial and Strategic SWOT Analysis Review

  • Published: April 2013
  • Region: Global
  • 40 pages
  • GlobalData

FEATURED COMPANIES

  • Allergan, Inc.
  • Pfizer Inc.
  • Targacept, Inc.
  • MORE

Summary

Acadia Pharmaceuticals Inc. (Acadia) is a biopharmaceutical company, engaged in discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company focuses on developing a portfolio of four advanced product candidates such as Pimavanserin, which is in phase III development for Parkinson’s disease psychosis. In, addition, the company is developing AGN XX/YY, a phase II for chronic pain and AC-262271 in phase I for glaucoma in collaboration with Allergan as well as IND-track development in collaboration with Meiji Seika Keisha. Acadia has established collaboration partnerships with companies like Biovail, Allergen Inc.

ACADIA Pharmaceuticals Inc. Key Recent Developments

Dec 20, 2012: EMD Serono And Fast Forward Announce Recipients Of Funding For Multiple Sclerosis Research
Nov 05, 2012: Acadia Pharma Reports Q3 2012 Results
Aug 08, 2012: Acadia Pharma Reports Q2 2012 Results
May 08, 2012: Acadia Reports Revenue Of $0.4m In Q1 2012
Mar 06, 2012: ACADIA Pharma Reports Q4 2011 Results

This comprehensive SWOT profile of ACADIA Pharmaceuticals Inc. provides you an in-depth READ MORE >

List of Tables
List of Figures
Section 1 - About the Company
ACADIA Pharmaceuticals Inc. - Key Facts
ACADIA Pharmaceuticals Inc. - Key Employees
ACADIA Pharmaceuticals Inc. - Key Employee Biographies
ACADIA Pharmaceuticals Inc. - Major Products and Services
ACADIA Pharmaceuticals Inc. - Pharmaceutical Pipeline Products Data
ACADIA Pharmaceuticals Inc., Pipeline Products by Therapy Area
ACADIA Pharmaceuticals Inc., Pipeline Products by Development Phase
ACADIA Pharmaceuticals Inc. - History
ACADIA Pharmaceuticals Inc. - Company Statement
ACADIA Pharmaceuticals Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
ACADIA Pharmaceuticals Inc. - Business Description
ACADIA Pharmaceuticals Inc. - Corporate Strategy
ACADIA Pharmaceuticals Inc. - SWOT Analysis
SWOT Analysis - Overview
ACADIA Pharmaceuticals Inc. - Strengths
Strength - Focused Research and Development
Strength - Strong Patent Portfolio
Strength - Technological base
ACADIA Pharmaceuticals Inc. - Weaknesses
Weakness - Lack of product based revenues
ACADIA Pharmaceuticals Inc. - Opportunities
Opportunity - Strong Product Pipeline
Opportunity - Strategic Collaborations and Agreements
Opportunity - Market Potential – CNS Therapy
Opportunity - Changing Demographics
ACADIA Pharmaceuticals Inc. - Threats
Threat - Intense Competition
Threat - Uncertain R&D Outcomes
Threat - Stringent Government Regulations
ACADIA Pharmaceuticals Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
ACADIA Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
ACADIA Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
ACADIA Pharmaceuticals Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
ACADIA Pharmaceuticals Inc., Recent Developments
Dec 20, 2012: EMD Serono And Fast Forward Announce Recipients Of Funding For Multiple Sclerosis Research
Nov 05, 2012: Acadia Pharma Reports Q3 2012 Results
Aug 08, 2012: Acadia Pharma Reports Q2 2012 Results
May 08, 2012: Acadia Reports Revenue Of $0.4m In Q1 2012
Mar 06, 2012: ACADIA Pharma Reports Q4 2011 Results
Jan 30, 2012: ACADIA Pharma Elects Bill Wells To Board
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
ACADIA Pharmaceuticals Inc., Key Facts
ACADIA Pharmaceuticals Inc., Key Employees
ACADIA Pharmaceuticals Inc., Key Employee Biographies
ACADIA Pharmaceuticals Inc., Major Products and Services
ACADIA Pharmaceuticals Inc., Number of Pipeline Products by Therapy Area
ACADIA Pharmaceuticals Inc., Number of Pipeline Products by Development Stage
ACADIA Pharmaceuticals Inc., Pipeline Products By Therapy Area and Development Phase
ACADIA Pharmaceuticals Inc., History
ACADIA Pharmaceuticals Inc., Subsidiaries
ACADIA Pharmaceuticals Inc., Key Competitors
ACADIA Pharmaceuticals Inc., Ratios based on current share price
ACADIA Pharmaceuticals Inc., Annual Ratios
ACADIA Pharmaceuticals Inc., Interim Ratios
ACADIA Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
ACADIA Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
ACADIA Pharmaceuticals Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
ACADIA Pharmaceuticals Inc., Pipeline Products by Therapy Area
ACADIA Pharmaceuticals Inc., Pipeline Products by Development Phase
ACADIA Pharmaceuticals Inc., Performance Chart (2007 - 2011)
ACADIA Pharmaceuticals Inc., Ratio Charts
ACADIA Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
ACADIA Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013

Alseres Pharmaceuticals, Inc.
Targacept, Inc.
Vanda Pharmaceuticals Inc.
Allergan, Inc.
Pfizer Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS